Bradley Merrill Thompson, a Member of the Firm in the Health Care and Life Sciences practice, in the Washington, DC, office, was quoted in “Quinn Leaves FCC Health Unit After Short Stint.”
Following is an excerpt:
According to Bradley Merrill Thompson, an attorney at Washington, D.C.-based law firm Epstein Becker Green who counsels medical device companies on regulatory issues, Quinn’s departure from FCC is “a setback for the mobile health initiative and comes at a critical time,” as the three agencies are finalizing their FDASIA report.
“I’m hoping that the final report is largely written, and is now being reviewed by senior management at the three agencies for approval,” said Thompson. “If it is not done, I fear that Matt’s departure will delay the completion of that report.”
“Regardless, we are on the verge of significant changes in the way health information technology is regulated, and whoever is asked to fill Matt’s shoes will be starting the race a good distance behind the line,” he added. “Matt has spent the last year deeply involved in the FDASIA process, listening to all the different stakeholders. Whoever comes in will be at a disadvantage not having lived through that feedback process.”